Role of Microbiome in the Realm of Immune Checkpoint Inhibitor Induced GI Complications in the Cancer Population (Phase I)

All Cancers
Active Trial
Yinghong Wang, MD
The University of Texas MD Anderson Cancer Center

Summary:

This trial is building on the Phase I I-SPY-2 trial which identified several biomarkers that predicted effective response rates to a group of therapeutic agents. Dr. Petricoin and team are now testing additional biomarkers using a new tool, the Reverse Phase Protein Microarray (RPPA). The team will focus on biomarkers in Stage II and II breast cancer patients, hopefully identifying additional biomarkers and related therapeutic agents that result in a complete response to the treatment. If successful, the RPPA tool could lead to new and improved patient-specific treatments for patients diagnosed with Stage II and III breast cancer.